Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. (Q48326651)

10 February 2018

title

Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. (English)

1 reference

10 February 2018

1 reference

Ozlem Yildiz

1

1 reference

10 February 2018

Sahika G Sismanlar

2

1 reference

10 February 2018

Nursu Cakin Memik

3

1 reference

10 February 2018

Isik Karakaya

4

1 reference

10 February 2018

Belma Agaoglu

5

1 reference

10 February 2018

publication date

1 June 2011

1 reference

10 February 2018

Child Psychiatry and Human Development

published in

1 reference

10 February 2018

volume

42

1 reference

10 February 2018

page(s)

257-269

1 reference

10 February 2018

issue

3

1 reference

10 February 2018

https://scigraph.springernature.com/pub.10.1007/s10578-010-0212-3

exact match

0 references

cites work

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Alternative (nonstimulant) medications in the treatment of attention-deficit/hyperactivity disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: the state of the field and salient challenges for the coming decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Executive function profile of children with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Studies of interference in serial verbal reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10578-010-0212-3

A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21165694

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21165694

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10578-010-0212-3

1 reference

10 February 2018

PubMed ID

21165694

1 reference

10 February 2018